An international collaborative study has identified several novel derivatives of anticancer proteasome inhibitors (PIs) that had potential as antimalarials, the authors reported in the September 28, 2021, online edition of Proceedings of the National Academy of Sciences.

Researchers at the National Institutes of Neurological Disorders and Stroke have demonstrated that systemic infections after either traumatic brain injury or cerebrovascular injury impair the repair of blood vessels by competing for the services of immune cells, in particular, proangiogenic myeloid cells.

Trimers of nanobodies, a simpler form of antibody made by some animal species, were effective at preventing and treating COVID-19 in preclinical studies, researchers reported in the Sept. 22, 2021, issue of Nature Communications. The findings, along with others, could form the basis of an inhaled biologics treatment for COVID-19 and, ultimately, other respiratory diseases.

A multicenter study led by scientists at Monash Institute of Pharmaceutical Sciences in Melbourne, Australia, has described a new mesenteric lymph vessel-based pathogenic mechanism, which was shown to contribute to visceral fat accumulation and insulin resistance in both mice and humans.

Trimers of nanobodies, a simpler form of antibody made by some animal species, were effective at preventing and treating COVID-19 in preclinical studies, researchers reported in the Sept. 22, 2021, issue of Nature Communications.

Although targeted therapies are prescribed on the basis of a patient's molecular makeup, they do not work every time. And in those instances where they do work, they basically stop working every time. In response, researchers have developed a number of systems whose goal it is to predict which drugs will be effective for an individual patients.

Researchers have retrospectively divided more than 16,000 non-small-cell lung cancer (NSCLC) patients with EGFR mutations into four structure-based subgroups, and looked at how the members of each subgroup fared depending on which EGFR inhibitor they were given.

Researchers have retrospectively divided more than 16,000 non-small-cell lung cancer (NSCLC) patients with EGFR mutations into four structure-based subgroups, and looked at how the members of each subgroup fared depending on which EGFR inhibitor they were given.

Investigators at MD Anderson Cancer Center have published data suggesting that activating KRAS mutations may be selected for in pancreatitis, because they protect pancreatic tissue from damage.

Researchers at Curtin University in Perth, Australia, have discovered that leakage from blood into the brain of fat-carrying particles transporting toxic proteins are a possible cause of Alzheimer's disease.